These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 2616358)
41. Chronic hemodialysis with the hollow fiber artificial kidney (HFAK). Gotch F; Lipps B; Weaver J; Brandes J; Rosin J; Sargent J; Oja P Trans Am Soc Artif Intern Organs; 1969; 15():87-96. PubMed ID: 5791436 [No Abstract] [Full Text] [Related]
42. The immune status of the uremic patient: hemodialysis vs CAPD. Schollmeyer P; Bozkurt F Clin Nephrol; 1988; 30 Suppl 1():S37-40. PubMed ID: 3052959 [TBL] [Abstract][Full Text] [Related]
43. Rationale for the use of a low molecular weight heparin during hemodialysis with polysulphone membrane in uremic patients. Moia M; Graziani G; Tenconi PM; Martinelli I; Ponticelli C Ann Ital Med Int; 1997; 12(2):67-71. PubMed ID: 9284597 [TBL] [Abstract][Full Text] [Related]
44. [Immunological parameters in uremic patients under hemodialysis]. Pigareva NV; Polenova IM Klin Med (Mosk); 1981 Mar; 59(3):75-9. PubMed ID: 7265837 [No Abstract] [Full Text] [Related]
45. Development of urease-chitosan membrane. Krajewska B; Leszko M; Zaborska W Polim Med; 1990; 20(1-4):31-41. PubMed ID: 2129516 [TBL] [Abstract][Full Text] [Related]
46. [Hemodialysis without acetate in closed circuit in chronic hemodialysis treatment of 3 patients with primary acetate intolerance]. Giorcelli G; Vacha G; Bergia R; Fruttero B; Bruno M; Zanfei A Minerva Nefrol; 1979; 26(1):79-81. PubMed ID: 471328 [No Abstract] [Full Text] [Related]
47. Removal of waste metabolites in uremia by microencapsulated reactants. Sparks RE; Salemme RM; Meier PM; Litt MH; Lindan O Trans Am Soc Artif Intern Organs; 1969; 15():353-9. PubMed ID: 5791409 [No Abstract] [Full Text] [Related]
48. [Changes in plasma levels of vitamin C during hemodialysis in patients with chronic uremia]. Dite P; Krch V; Groh J Tunis Med; 1968; 46(4):329-35. PubMed ID: 5713845 [No Abstract] [Full Text] [Related]
49. Contribution of high flux membranes to the therapy of uremia-associated dyslipidemia. Azak A; Huddam B; Öneç K; Koçak G; Dede F; Aylı D; Duranay M Ther Apher Dial; 2012 Dec; 16(6):595-9. PubMed ID: 23190521 [TBL] [Abstract][Full Text] [Related]
50. [Levels of tumor necrosis factor and interleukin 1 in uremia and in hemodialysis]. Peona C; Fortina A; Colombo P; Filiberti O; Cagna G; Costantini L; Porcu M Minerva Urol Nefrol; 1991; 43(3):175-9. PubMed ID: 1726274 [TBL] [Abstract][Full Text] [Related]
51. [Plasma catecholamines and chronic hypotension in hemodialysis]. Verzetti G; Picotti GB; Ravazzani C; Cavagnino A; Fortina F; De Leo M; Baroni A; Airoldi G; Schweiger C Minerva Nefrol; 1979; 26(1):95-9. PubMed ID: 471332 [No Abstract] [Full Text] [Related]
52. [Changes in various lymphocyte subpopulations in the peripheral blood of patients with chronic uremia during hemodialysis]. Kroczak M Pol Arch Med Wewn; 1989 Jun; 81(6):336-42. PubMed ID: 2634251 [TBL] [Abstract][Full Text] [Related]